The FDA first approved the marketing of this drug on May 21, 2021, primarily for patients with EGFR ex20ins mutations who were treated with platinum-based drugs and mutations in adult patients with locally advanced or metastatic NSCLC refractory to platinum therapy (88). This evidence concerns the gene EGFR and non-small cell lung carcinoma.